Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

What ENTA will be discussing at JPM:

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-provide-updates-its-research-and-3

• Progresses Phase 2 SPRINT Trial of EDP-235, an Oral, 3CL Protease Inhibitor for COVID-19, With Data Expected in 1H 2023

• Presents New Preclinical In Vivo Data Demonstrating EDP-235’s Efficacy and Prevention of COVID-19 Transmission

• Expands Robust COVID-19 Antiviral Portfolio With a New Research Program Developing SARS-CoV-2 Papain-Like Protease Inhibitors—[Note: This is a different target from EDP-235, which impedes the SARS-CoV-2 “main” protease—Dew.]

• Introduces New Research Program Targeting Human Metapneumovirus (hMPV) and Respiratory Syncytial Virus (RSV) with a Single Agent; Clinical Candidate Selection Targeted for 4Q 2023

[Emphasis added.] Alas, no update on a new HBV candidate to combine with EDP-514, although the above PR contains one paragraph (at the bottom) reiterating ENTA’s purported interest in HBV. IMO, it’s reasonable to surmise that ENTA is unwilling to dedicate much effort to finding a second HBV agent, and is prepared out-license EDP-514 on suitable terms.